Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?

Summary

Th mechanism of action of dapagliflozin is via sodium-glucose co-transporter 2 (SGLT2) inhibition. Sodium-glucose co-transporter 2 inhibition is associated with moderate weight (fat) loss, in addition to other health benefits, including decreased blood pressure, decreased inflammation, and decreased oxidative stress. It is unclear as to whether these health benefits are due to SGLT2 inhibition per se, or as a secondary effect of weight loss.

Timeline

Start

2015-08

Primary completion

2017-05

Completion

2017-05

Outcome

Outcome not reported

Stopped: “Designed a new modified/simplified protocol see NCT 03180489”

Drugs

Indications

No indication recorded.